Skip to content

Gross margin at other companies

Amgen logo
AmgenAMGN
68.3%+5.3pp
Gilead Sciences logo
Gilead SciencesGILD
79.4%+1.1pp
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
36.7%+4.1pp
Nuvation Bio logo
Nuvation BioNUVB
54.3%+39.5pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
99.3%-0.5pp
Moderna logo
ModernaMRNA
22.1%-32.0pp

Other financials

Income statement

See full
Revenue-$29.0K-101%
Gross profit$1.2M-60.2%
Operating income-$132.3M+5.2%
Net income-$125.7M-3.9%
EPS (diluted)-$0.85+3.4%

Balance sheet

See full
Cash & equivalents$283.0M-23.1%
Total debt$95.6M-0.5%
Total equity$812.8M-22.1%
Total assets$1.0B-21.6%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$390.0K-76.1%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.71B+61.1%
Enterprise value$1.53B+102%
P/S26.2×-24.8×

Profitability

See full
Operating margin-720.8%-313pp
Net margin-676%-291pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-47.7%+3.6pp
Debt / equity0.1×0.0×
Current ratio7.1×+0.3×

Where this comes from

Calculated from Vir Biotechnology, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Vir Biotechnology, Inc.’s 10-Q, filed August 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Vir Biotechnology, Inc.'s gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vir Biotechnology, Inc.'s gross margin?
Vir Biotechnology, Inc. (VIR) reported gross margin of 96.1% in Q2 2025.
How has Vir Biotechnology, Inc.'s gross margin changed year-over-year?
Vir Biotechnology, Inc.'s gross margin decreased by 2.8% year-over-year, from 98.8% to 96.1%.
What is the long-term trend for Vir Biotechnology, Inc.'s gross margin?
Over 4 years (2020 to 2024), Vir Biotechnology, Inc.'s gross margin has grown at a -0.3% compound annual growth rate (CAGR), from 100% to 98.9%.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.